Testosterone treatment in women - An overview

Current Women's Health Reviews

Volumn 5, Issue 1, 2009, Pages 29-43

  Rådestad, Angelique Flöter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Androgens; Body composition; Bone; Female androgen insufficiency; Lipids; Oophorectomy; Sexual function; Testosterone; Well being

Indexed keywords

ANDROGEN RECEPTOR; ESTRATEST; ESTROGEN; METHYLTESTOSTERONE; NANDROLONE DECANOATE; PLACEBO; PRASTERONE; PROGESTERONE; TESTOSTERONE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

ACNE; ALOPECIA; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; BLOOD CLOTTING DISORDER; BODY COMPOSITION; BONE METABOLISM; BREAST CANCER; BREAST DISEASE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CLITORIS HYPERTROPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE ANDROGEN INSUFFICIENCY; FEMALE SEXUAL DYSFUNCTION; GYNECOLOGIC DISEASE; HAIR GROWTH; HIRSUTISM; HOARSENESS; HORMONE ACTION; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOPHYSIS DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER CELL DAMAGE; LIVER DISEASE; LIVER FUNCTION TEST; LOW DRUG DOSE; MUSCLE ATROPHY; NONHUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMATURE OVARIAN FAILURE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SEXUAL FUNCTION; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET ORGAN; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SYNTHESIS; TRANSDERMAL PATCH; TURNER SYNDROME; VASOMOTOR DISORDER; VIRILIZATION; WEIGHT GAIN; WOMEN'S HEALTH;

EID: 65949113409     PISSN: 15734048     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340409787721267     Document Type: Review

References (163)

1. Crilly RG, Francis RM, Nordin BE. Steroid hormones, ageing and bone. Clin Endocrinol Metab 1981; 10: 115-39.
2. Vermeulen A. Plasma androgens in women. J Reprod Med 1998; 43: 725-33.
3. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four hour mean plasma testosterone concentrations decline with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80: 1429-30.
4. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000; 85: 2832-38.
5. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24: 152-82.
6. Davison SL, Bell R, Donath S, Monalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-53.
7. Judd HL, Judd GE, Lucas WE, Yen SS. Endocrine function of the postmenopausal ovary: concentrations of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974; 39: 1020-24.
8. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo study. J Clin Endocrinol Metab 2000; 85: 645-51.
9. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005; Oct 19; (4): CD004509.
10. Davis SR, McCloud PI, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995; 21: 227-36.
11. Watts NB, Notelovitz M, Timmons MC. Comparison of oral estrogens and estrogen plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995; 85: 529-37.
12. Barrett-Connor E, Young R, Notelovitz M. A two-year double-blind comparison of estrogen-androgen and conjugated estrogens in surgically PM women: effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999; 44: 1012-20.
13. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 2000; 7: 395-401.
14. Gruber DM, Sator MO, Kirchengast S, Joura EA, Huber JC. Effects of percutaneous replacement therapy on body composition and body weight in postmenopausal women. Maturitas 1998; 29: 253-59.
15. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 1509-16.
16. Speroff L, Fritz M (ed.). In: Clinical gynecologic endocrinology and infertility. London, Williams and Wilkins Co. 2004; 515.
17. Rannevik G, Carlstrom K, Jeppsson S, Bjerre B, Svanberg L. A prospective long-term study in women from premenopause to postmenopause: changing profiles of gonadotrophins, oestrogens and androgens. Maturitas 1986; 8: 297-307.
18. Jiroutek MR, Chen M-H, Johnston CC. Changes in reproductive hormones and sex hormone-binding globulin in a group of postmenopausal women measured over 10 years. Menopause 1998; 5: 90-94.
19. Longcope C, Franz C, Morello C, Baker R, Johnston CC Jr. Steroid and gonadotropin levels in women during the perimenopausal years. Maturitas 1986; 8: 189-96.
20. Guay A, Munarriz R, Jacobson J, et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part B: Reduced serum androgen levels in healthy premenopausal women with complaints of sexual dysfunction. Int J Impot Res 2004; 16:121-29.
21. Aiman J, Forney JP, Parker CR jr. Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women. Obstet Gynecol 1986; 68: 1-5.
22. Ala-Fossi S-L, Mäenpää J, Aine R, Punnonen R. Ovarian testosterone secretion during perimenopause. Maturitas 1998; 29: 239-45.
23. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001; 56: 361-75.
24. Judd HE, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974; 118: 793-98.
25. Hughes CL Jr, Wall LL, Creasman WT. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol 1991; 40: 42-45.
26. Aziz A, Brännström M, Bergquist C, Silfverstolpe G. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005; 83: 1021-28.
27. Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660-65.
28. Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope dilution gas chromatography-mass spectrometry in sera from 116 men, women and children. Clin Chem 2003; 49: 381-95.
29. Couzinet B, Meduri G, Lecce MG, et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001; 86: 5060-66.
30. Pardridge WM. Serum bioavailability of sex hormones. In: Pardridge WM (ed). Clin Endocrinol Metab 1986; 15: 259-78.
31. Gershagen S, Doeberl A, Jeppsson S, Rannevik G. Decreasing serum levels of sex hormone-binding globulin (SHBG) around the menopause and temporary relation to changing levels of ovarian steroids, as demonstrated in a longitudinal study. Fertil Steril 1989; 51: 616-20.
32. Lobo RA, Rosen RC, Yang H-M, Block B, van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in post-menopausal women with hypoactive sexual desire. Fertil Steril 2003; 79: 1341-51.
33. Tazuke S, Khaw K-T, Barrett-Connor E. Exogenous estrogens and endogenous sex hormones. Medicine 1992; 71: 44-50.
34. Gower BA, Nyman L. Associations among oral estrogen use, free testosterone concentration, and lean body mass among post-menopausal women. J Clin Endocrinol Metab 2000; 85: 4476-80.
35. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen and androgen receptors: dissociation from transcriptional activity. Cell 2001; 104: 719-30.
36. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148: 281-92.
37. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocrine Rev 1987; 8:1-28.
38. Sherwin BN, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective crossover study of sex steroid administration in surgical menopause. Psychosom Med 1985; 47: 339-51.
39. Flöter A, Nathorst-Böös J, Carlström K, von Schoultz B. Androgen status and sexual life in perimenopausal women. Menopause 1997; 4: 95-100.
40. Guay A, Jacobson J. Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J Sex Marital Ther 2002; 28: 129-42.
41. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987; 49: 397-409.
42. Nathorst-Böös J, von Schoultz B, Carlström K. Elective ovarian removal and estrogen replacement therapy: effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 1993; 14: 283-93.
43. Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hysterectomy and sexual functioning. JAMA 1999; 282: 1934-41.
44. Mazer NA, Leiblum SR, Rosen RC. The brief index of sexual functioning for women (BISF-W): a new scoring algorithm and comparison of normative and surgically menopausal populations. Menopause 2000; 7: 350-63.
45. Laumann EO, Paik A, Rosen R. Sexual dysfunction in the United States. Prevalence and Predictors. JAMA 1999; 281: 537-44.
46. Myers LS, Dixen J, Morristte D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990; 70: 1124-31.
47. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-88.
48. Penotti M, Sironi L, Cannata L et al. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil Steril 2001; 76: 235-40.
49. Flöter A, Nathorst-Böös J, Carlström K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric 2002; 5: 357-65.
50. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003; 10: 390-98.
51. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226-33.
52. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Arch Intern Med 2005; 165: 1582-89.
53. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105: 944-52.
54. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause 2006; 13: 770-79.
55. Davis SR, van der Mooren MJ, van Lunsen RH, et al. Efficacy and safety of testosterone patch for treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause 2006; 13: 387-96.
56. Nathorst-Böös J, Flöter A, Jarkander-Rolff M, Carlström K, Schoultz B. Treatment with percutaneous testosterone gel in postmenopausal women with decreased libido-effects on sexuality and psychological general well-being. Maturitas 2006; 53:11-18.
57. Davis S, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 2008; 148: 569-77.
58. McEwen BS, Davis PG, Jellinck PH, et al. Steroid hormone receptors, brain cell function, and the neuroendocrine system. Adv Biochem Psychopharmacol 1980; 21: 383-90.
59. Genazzani AR, Monteleone P, Gambacciani M. Hormonal influence on the central nervous system. Maturitas 2002; 43: 11-17.
60. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer anti-depressants. J Clin Psychiatry 2002; 63: 357-66.
61. Traish AM, Kim N, Min K, Munarriz R, Goldstein I. Role of androgens in female genital sexual arousal: receptor expression, structure and function. Fertil Steril 2002; 77: 11-18.
62. Goldstein I. Female sexual arousal disorder: new insights. Int J Impot Res 2000; 12: 152-57.
63. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in post-menopausal women. Climacteric 2001; 4: 28-41.
64. Basson R. Using a different model for female sexual response to address women's problematic low sexual desire. J Sex Marital Ther 2001; 27: 395-403.
65. Basson R. Rethinking low sexual desire in women. Br J Obstet Gynecol 2002; 109: 357-63.
66. McCoy NL. Female sexuality during aging. In: Hof & Mobbs (eds). Functional Neurobiology of aging. San Diego CA, Academic Press, 2001; 769-79.
67. McHorney CA, Rust J, Golombok S, et al. Profile of female sexual function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. Menopause 2004; 11: 474-83.
68. Rosen RC. Assessment of female sexual dysfunction: review of validated methods. Fertil Steril 2002; 77: 89-93.
69. Rosen RC, Lobo RA, Block BA, et al. Menopausal sexual interest questionnaire (MSIQ): a unidimensional scale for the assessment of sexual interest in postmenopausal women. J Sex Marital Ther 2004; 30: 235-50.
70. Meston CM. Validation of the female sexual function index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther 2003; 29: 39-46.
71. Goldstein I, Berman J. Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int J Impot Res 1998; 10: 84-90.
72. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985; 151: 153-60.
73. Mazer NA. Testosterone deficiency in women: etiologies, diagnosis, and emerging treatments. Int J Fertil 2002; 47: 77-86.
74. O'Connor VM, del Mar CB, Sheehan M, et al. Do psychosocial factors contribute more to symptom reporting by middle-aged women than hormonal status? Maturitas 1995; 20: 63-69.
75. Dennerstein L, Smith AM, Morse C. Psychological well-being, midlife and the menopause. Maturitas 1994; 20: 1-11.
76. Skarsgård C, Berg GE, Ekblad S, Wiklund I, Hammar ML. Effects of estrogen therapy on well-being in postmenopausal women without vasomotor complaints. Maturitas 2000; 36: 123-30.
77. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord 1988; 14: 177-87.
78. Davis SR. The effects of tibolone on mood and libido. Menopause 2002; 9: 162-70.
79. Barrett-Connor E, von Mühlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 1999; 47: 685-91.
80. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360-67.
81. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341: 1013-19.
82. Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84: 3896-3902.
83. Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 2046-52.
84. Dupuy HJ. The psychological general well-being (PGWB) index. In: Assessment of quality of life in clinical trials of cardiovascular therapies. Le Jacq Publishing Inc. New York, USA. 1984; 170-83.
85. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004; 25: 389-425.
86. Hashimoto K, Nozaki M, Yokoyama M. Urinary excretion of pyridinium crosslinks of collagen in oophorectomized women as markers for bone resorption. Maturitas 1994; 18: 135-42.
87. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996; 81: 37-43.
88. Flöter A, Nathorst-Böös J, Carlström K, Ohlsson C, Ringertz H, von Schoultz B. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. Gynecol Endocrinol 2005; 20: 155-60.
89. Sands RH, Studd JW, Jones J, Alaghband-Zadeh J. Comparison of the biochemical effects of testosterone and estrogen on bone markers in surgically postmenopausal women. Gynecol Endocrinol 2000; 14: 382-87.
90. Savvas M, Studd JW, Norman S, Leather AT, Garnett TJ, Fogelman I. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynecol 1992; 99: 757-60.
91. Douchi T, Yamamoto S, Nakamura S, et al. The effect of menopause on regional and total body lean mass. Maturitas 1998; 29: 247-52.
92. Guo SS, Zeller C, Chumlea WC, Siervogel RM. Ageing, body composition and lifestyle: the Fels longitudinal study. Am J Clin Nutr 1999; 70: 405-11.
93. Lapidus L, Bengtsson C, Björntorp P, et al. Androgens and women's health: genetic and epidemiologic aspects of lipid metabolism. Am J Med 1995; 98: 1-26.
94. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol Endocrinol Metab 1995; 32: 820-26.
95. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1-7.
96. Lovejoy JC, Bray GA, Bourgeois MO. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 2198-2203.
97. Despres J-P, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511.
98. Khatibi A, Agardh CD, Shakir YA, et al. Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study. Climacteric 2007; 10: 386-92.
99. Haffner SM, Dunn JF, Katz MS. Relationship of sex hormone-binding globulin to lipid, lipoprotein, glucose, and insulin concentrations in postmenopausal women. Metabolism 1992; 41: 278-84.
100. Andersson B, Mårin P, Lissner L, et al. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405-11.
101. Mårin P, Holmäng S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obesity Res 1993; 1: 245-51.
102. Zang H, Carlström K, Arner P, Hirschberg AL. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 2006; 86: 136-44.
103. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996; 24: 1-19.
104. Juhan-Vague I, Vague P. Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease. Am J Obstet Gynecol 1990; 163: 313-15.
105. Winkler UH. Effects of androgens on haemostasis. Maturitas 1996; 24: 147-55.
106. Buckler HM, McElhone K, Durrington PN, Mackness MI, Ludlam CA, Wu FC. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol 1998; 49: 173-78.
107. Worboys S, Kotsopoulos D, Teede H, McGrawth B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and - independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001; 86: 158-61.
108. Chiuve SE, Martin LA, Campos H, Sacks FM. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. J Clin Endocrinol Metab 2004; 89: 2207-13.
109. Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the second joint Task Force of European and other societies on coronary prevention. Atherosclerosis 1998; 140: 199-270.
110. Goh HH, Loke DF, Ratnam SS. The impact of long-term testosterone replacement therapy on lipid and lipoprotein profiles in women. Maturitas 1995; 21: 65-70.
111. Shepherd J. Danazol and plasma lipoprotein metabolism. Int J Gynecol Obstet 1995; 50: 23-26.
112. Sherwin BB, Gelfand MM, Schucher R, Gabor J. Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations. Am J Obstet Gynecol 1987; 156: 414-19.
113. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993; 82: 919-24.
114. Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six month trial. Fertil Steril 1998; 70: 107-10
115. Buckler HM, Robertson WR, Wu FC. Which androgen replacement therapy for women? J Clin Endocrinol Metab 1998; 83: 3920-24.
116. Flöter A, Nathorst-Böös J, Carlström K, von Schoultz B. Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy. Maturitas 2004; 47: 123-29.
117. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006; 91: 3697-710.
118. Simon JA. Estrogen replacement therapy: effects on the endogenous androgen milieu. Fertil Steril 2002; 4: 77-82.
119. Davis SR, Tran J. Testosterone influences libido and well-being in women. Trends Endocrinol Metab 2001; 12: 33-37.
120. Slayden SM. Risks of menopausal androgen supplementation. Semin Reprod Endocrinol 1998; 16: 145-52.
121. Simon JA. Safety of estrogen/androgen regimens. J Reprod Med 2001; 46: 281-90.
122. Nieschlag E, Mauss J, Coert A, Kicovic P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol 1975; 79: 366-74.
123. Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84: 3896-902.
124. Shackleford DM, Faassen WA, Houwing N, et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther 2003; 306: 925-33.
125. Flöter A, Carlström K, von Schoultz B, Nathorst-Böös J. Administration of testosterone undecanoate in postmenopausal women: effects on androgens, estradiol and gonadotrophins. Menopause 2000; 7: 251-56.
126. Nathorst-Böös J, Jarkander-Rolff M, Carlström K, Flöter A, von Schoultz B. Percutaneous administration of testosterone gel in postmenopausal women-a pharmacological study. Gynecol Endocrinol 2005; 20: 243-48.
127. Duffy DM, Legro RS, Chang L, Stanczyk FZ, Lobo RA. Metabolism of dihydrotestosterone to 5 alpha-androstane-3alpha, 17 beta-diol glucuronide is greater in the peripheral compartment than in the splanchnic compartment. Fertil Steril 1995; 64: 736-39.
128. Cardozo L, Gibb DM, Tuck SM, Thom MH, Studd JW, Cooper DJ. The effects of subcutaneous hormone implants during climacteric. Maturitas 1984; 5: 177-84.
129. Barrett-Connor E, Timmons C, Young R. Interim safety analysis of a two year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. J Women's Health 1996; 5: 593-602.
130. Urman B, Pride SM, Ho Yuen B. Elevated serum testosterone, hirsutism, and virilization associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 1991; 77: 595-98.
131. Gerritsma EJ, Brocaar MP, Hakkesteegt MM, Birkenhager JC. Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate (Decadurabolin). The effects of medication for one year. Clin Otolaryngol 1994; 19: 79-84.
132. Phillips EH, Ryan S, Ferrari R, Green C. Estratest and Estratest HS (esterified estrogens and methyltestosterone) therapy: a summary of safety surveillance January 1989 to August 2002. Clin Ther 2003; 25: 3027-43.
133. Westaby D, Ogle SJ, Murray-Lyon IM, et al. Liver damage from long-term methyltestosterone. Lancet 1077; 8032: 261-63.
134. Somboonporn W, Davis SR: National health and medical research council. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004; 25: 374-99.
135. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomised controlled trial. JAMA 2002; 288: 321-33.
136. Dimitrakakis C, Zhou J, Wang J, et al. A physiological role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10: 292-98.
137. Hofling M, Lundström E, Azavedo E, Svane G, Hirschberg AL, von Schoultz B. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. Climacteric 2007; 10: 155-63.
138. Lobaccaro JM, Lumbroso S, Belon C, et al. Male breast cancer and the androgen receptor gene. Nat Genet 1993; 5: 109-10.
139. Haiman CA, Brown M, Hankinson SE, et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res 2002; 62: 1045-49.
140. Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001; 65: 163-69.
141. Conner P, Christow A, Kersemaekers W, et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment. Climacteric 2004; 7: 50-58.
142. Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991; 134: 818-24.
143. Mertens HJ, Heineman MJ, Theunissen PH, de Jong FH, Evers JL. Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. Eur J Obstet Gynecol Reprod Biol 2001; 98: 58-65.
144. Lovely LP, Appa Rao KB, Gui Y, Lessey BA. Characterization of androgen receptors in well-differentiated endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem Mol Biol 2000; 74: 235-41.
145. Sasaki M Sakuragi N, Dahiya R. The CAG repeats in exon 1 of the androgen receptor gene are significantly longer in endometrial cancer patients. Biochem Biophys Res Commun 2003; 305: 1105-8.
146. Narvekar N, Cameron S, Critchley HO, Lin S, Cheng L, Baird DT. Low-dose mifepristone inhibits endometrial proliferation and regulates androgen receptor. J Clin Endocrinol Metab 2004; 89: 2491-97.
147. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002; 11: 1531-43.
148. Shelley DR, Dunaif A. Polycystic ovary syndrome. Compr Ther 1990; 16: 26-34.
149. Möllerström G, Lagrelius A, Carlström K, Einhorn N. Is there an altered steroid profile in patients with endometrial carcinoma? Cancer 1993; 72: 173-81.
150. Jongen VH, Hollema H, van der Zee AG, Santema JG, Heineman MJ. Ovarian stromal hyperplasia and ovarian vein steroid levels in relation to endometrioid endometrial cancer. Br J Obstet Gynecol 2003; 110: 690-95.
151. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004; 108: 425-32.
152. Gelfand MM, Ferenczy A, Bergeron C. Endometrial response to estrogen-androgen stimulation. In: Hammond C, Hazeltine F, Schiff (Eds). Menopause: evaluation, treatment, and health concerns. Liss AR Inc. 1989; 29-40.
153. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997; 82: 3498-3505.
154. Zang H, Sahlin L, Masironi B, Eriksson E, Lindén Hirschberg A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 2169-75.
155. Hagenfeldt K, Ritzén ME, Ringertz H, Helleday J, Carlström K. Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy. Eur J Endocrinol 2000; 143: 667-71.
156. Hampson G, Bhargava N, Cheung J, Vajas S, Seed PT, Fogelman I. Low circulating estradiol and adrenal androgen concentrations in men on glucocorticoids: a potential contributory factor in steroid induced osteoporosis. Metabolism 2002; 51: 1458-62.
157. Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with kariotypically normal spontane premature ovarian failure. Obstet Gynecol 1998; 91: 12-15.
158. Bloch M, Schmidt PJ, Su TP, Tobin MB, Rubinow DR. Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls. Biol Psychiat 1998; 43: 897-903.
159. Cutolo M. Sex hormone adjuvant therapy in rheumatoid arthritis. Rheum Dis Clin North Am 2000; 26: 881-95.
160. Van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998; 25: 285-89.
161. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with aquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 1998;83: 2717-25.
162. Notelovitz M. Hot flashes and androgens: a biological rationale for clinical practice. Mayo Clin Proc 2004; 79: 8-13.
163. Miller K, Grieco K, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 2005; 90:1428-33.